Overcoming major healthcare challenges such as cancer and autoimmunity is of primary importance for the EU. To develop new diagnostic, preventive or therapeutic approaches for these diseases, Europe needs to invest in relevant research and technology transfer activities.
The EU-funded INNOMOL (Enhancement of the innovation potential in SEE through new molecular solutions in research and development) initiative fostered a research pipeline at the Rudjer Boskovic Institute (RBI) in Croatia. The scope was to facilitate new avenues of innovation and technology for the investigation of relevant diseases. Through the establishment of a centre of excellence, INNOMOL sought to bridge the gap between research and valorisation of innovative products.
Further information: Molecular bioscience research in Croatia gets a boost from the EU